跳到正文
原文
梅斯医学·临床资讯·· 2 天前精选AI 评分65

谢雯教授团队4项肝病研究亮相2026 AASLD

中国之声 | 谢雯教授团队4项研究亮相2026 AASLD

AI 导读

首都医科大学附属北京地坛医院谢雯教授团队在2026 AASLD会议上展示了4项关于肝硬化、白蛋白应用及代谢功能障碍的研究,包括系统评价和网状Meta分析、横断面混合方法研究、电子顺磁共振技术检测白蛋白结合功能、以及艾米替诺福韦对慢性乙型肝炎合并代谢功能障碍相关脂肪性肝病患者的影响。

推荐理由

系统评价和网状Meta分析揭示了白蛋白在肝硬化治疗中的作用,为临床决策提供依据。

正文

深度解析医学证据,DeepEvidence为你支撑决策

2026年美国肝病研究学会年会(The Liver Meeting 2026,AASLD 2026)于11月5日-9日在美国科罗拉多州丹佛市隆重召开。作为全球肝病领域一年一度的顶级学术盛会,本次大会汇集国内外专家学者,聚焦肝病前沿热点,分享多项重磅原创研究成果。

首都医科大学附属北京地坛医院谢雯教授团队四项围绕肝硬化白蛋白应用、白蛋白功能检测、以及艾米替诺福韦在合并 MASLD 慢乙肝人群中应用的研究精彩亮相大会。肝胆相照平台特整理该项研究核心内容,供广大临床同道参考学习。

一 1566

基于白蛋白的治疗方案及其他干预措施对失代偿期肝硬化患者低钠血症、血浆肾素活性和血清肌酐的疗效比较:系统评价与网状Meta分析

Comparative Efficacy of Albumin-Based and Other Interventions for Hyponatremia, Plasma Renin Activity, and Creatinine in Decompensated Cirrhosis: A Systematic Review and Network Meta-Analysis

作者:Wen Xie¹, Wanting Yang¹, Ligai Liu¹, Ruizhi Zheng², Hong Zhao¹, Yanbin Wang¹, Ying Cao¹

1 Beijing Ditan Hospital, Capital Medical University

2 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

背景

人血白蛋白输注广泛应用于失代偿期肝硬化的治疗,但随机对照试验(RCT)关于其对神经体液系统激活及肾功能影响的证据仍不一致。本研究通过系统评价和网状Meta分析(NMA),比较以人血白蛋白为基础的治疗方案及其他干预措施在降低低钠血症发生率、血浆肾素活性(PRA)和血清肌酐水平方面的疗效。

Background:Human albumin infusion is widely used in the treatment of decompensated cirrhosis, yet evidence from randomized controlled trials (RCTs) remains inconsistent regarding its effects on neurohumoral activation and renal function. We conducted a systematic review and network meta-analysis (NMA) to evaluate the comparative efficacy of human albumin-based and other interventions on hyponatremia incidence, plasma renin activity (PRA), and serum creatinine.

方法

研究系统检索了Web of Science、PubMed和Embase数据库,检索时间从建库至2025年2月,纳入评价人血白蛋白治疗失代偿期肝硬化患者疗效的随机对照试验。

研究比较了7种干预策略(A–G,具体分类见原文图例),主要结局指标包括治疗后低钠血症发生情况、PRA变化及血清肌酐变化。采用频率学派随机效应网状Meta分析进行统计,并通过累积排序曲线下面积(SUCRA)评估不同治疗方案的疗效排序。

系统评价注册号:PROSPERO CRD420261374214。

Methods:We searched Web of Science, PubMed, and Embase from inception to February 2025 for RCTs evaluating human albumin in patients with decompensated cirrhosis. Seven intervention strategies (A-G, see figure legend for details) were compared. Outcomes were post-treatment hyponatremia, changes in PRA and creatinine. A frequentist random-effects NMA was performed, and treatment rankings were estimated using surface under the cumulative ranking curve (SUCRA).

Systematic Review Registration: PROSPERO CRD420261374214.

 结果

本研究共纳入44项随机对照试验,涉及4771例患者。

在低钠血症结局方面,共纳入17项试验、1582例患者。与对照治疗相比,大容量腹腔穿刺放液(LVP)联合大剂量白蛋白(每升放出腹水补充白蛋白超过6 g)降低低钠血症发生风险的效果最佳,OR为0.12(95% CI:0.03–0.45),其SUCRA值最高,为87.2%。

在PRA结局方面,共纳入18项试验、1207例患者。除单独进行大容量腹腔穿刺放液外,大多数积极干预措施均能够抑制PRA升高。其中,LVP联合小剂量白蛋白的疗效排序最高,SUCRA值为88.3%。

在血清肌酐结局方面,共纳入28项试验、2134例患者。LVP联合其他胶体液或血管活性药物、单独使用白蛋白,以及LVP联合大剂量白蛋白均显示出一定程度的肌酐降低效果,但三者之间未发现显著差异。敏感性分析进一步支持了研究结果的稳健性。

Results:A total of 44 RCTs involving 4,771 participants were included. For hyponatremia (17 trials, n = 1,582), large volume paracentesis (LVP) combined with high-dosage albumin ( > 6 g/L ascites removed) was associated with the greatest reduction compared with control strategies (odds ratio [OR] 0.12, 95% CI 0.03–0.45) and had the highest ranking probability (SUCRA 87.2%).

For PRA (18 trials, n = 1,207), most active interventions, except LVP alone, inhibited PRA elevation, with LVP combined with low-dosage albumin showing the highest ranking (SUCRA 88.3%).

For serum creatinine (28 trials, n = 2,134), LVP combined with other colloids/vasoactive agents, albumin alone, and LVP combined with high-dosage albumin all demonstrated modest reductions versus control, with no significant differences among them. Sensitivity analyses supported the robustness of findings.

结论

对于失代偿期肝硬化患者,大容量腹腔穿刺放液联合大剂量白蛋白是降低低钠血症风险最有效的治疗方案。多种以白蛋白为基础的治疗方案均能够在一定程度上抑制肾素-血管紧张素-醛固酮系统(RAAS)激活,并有助于稳定PRA和血清肌酐水平。

Conclusion:In patients with decompensated cirrhosis, LVP combined with high-dosage albumin is the most effective treatment for reducing hyponatremia risk. Multiple albumin-based regimens similarly suppress renin-angiotensin-aldosterone system activation and stabilize PRA and creatinine.

二 1667

中国肝硬化患者诊疗历程及人血白蛋白使用模式分析:一项多中心横断面混合方法研究

Patient Journey Mapping of Liver Cirrhosis Management and Human Serum Albumin Utilization Patterns: A Multicenter Cross-pal Mixed-Methods Study in China

作者:Wen Xie¹, Yufei Zhan¹, Ligai Liu¹, Ying Cao¹, Hong Zhao¹, You Deng²

1 Beijing Ditan Hospital, Capital Medical University

2 Beijing Friendship Hospital, Capital Medical University

研究背景

中国面临较重的肝脏疾病负担。尽管人血白蛋白(HSA)广泛应用于肝硬化治疗,但目前对于中国真实世界中白蛋白的处方使用模式及其影响因素仍缺乏充分认识。本研究采用混合研究方法,旨在分析肝硬化患者在整个疾病诊疗过程中就医路径的特点,以及人血白蛋白的临床使用模式。

Background:China bears a substantial burden of liver disease. Although human serum albumin (HSA) is widely used in the treatment of cirrhosis, real-world prescribing patterns and factors influencing its use in China remain poorly characterized. This mixed-methods study aims to examine patient journeys and patterns of HSA use across the cirrhosis care continuum.

研究方法

这是一项在中国5家大型三级医院开展的多中心、横断面混合方法研究,计划纳入约1000例肝硬化患者,其中30%为代偿期肝硬化,70%为失代偿期肝硬化。

研究整合患者及医生访谈、病历资料提取和问卷调查等多种数据收集方式。定性访谈主要关注患者诊疗路径、白蛋白使用体验、经济负担及长期疾病管理情况,以分析临床决策过程及其影响因素。定量研究数据则包括肝硬化疾病分期、并发症、医疗服务可及性、经济负担以及白蛋白的使用模式等。

Methods:This multicenter, cross-pal, mixed-methods study is being conducted across five top-tier hospitals in China, with a planned enrollment of approximately 1,000 patients with cirrhosis, including 30% with compensated and 70% with decompensated disease.

The study integrates patient and physician interviews, medical record abstraction, and questionnaire-based data collection. Qualitative interviews focus on care pathways, experiences with HSA use, economic burden, and long-term disease management to characterize clinical decision-making processes and their determinants. Quantitative data include disease stage, complications, healthcare access, financial burden, and patterns of HSA use.

 研究结果

本研究基于临床诊疗路径及指南推荐,已经开发了以患者就医历程为基础的结构化调查问卷和访谈提纲。借助这些研究工具,研究拟系统描述中国肝硬化患者真实世界中的诊疗路径及人血白蛋白使用模式。研究将分析不同临床情境及并发症状态下白蛋白的使用情况,并评价其与临床指南推荐的一致性。此外,还将评估白蛋白使用相关的经济负担,以及医保报销政策对白蛋白治疗可及性的影响。

研究还将识别影响临床处方决策的关键因素,并从患者角度评价长期疾病管理的连续性及尚未满足的医疗需求。

Results:A patient journey–based structured questionnaire and interview guide have been developed based on clinical pathways and guideline recommendations. Using these tools, this study aims to characterize the real-world care pathways and patterns of HSA use among patients with cirrhosis in China.

It will examine HSA utilization across different clinical scenarios and complications, while also assessing concordance with guideline recommendations. Additionally, it will assess the economic burden associated with HSA use and the impact of reimbursement policies on treatment accessibility. Key factors influencing prescribing decisions will be identified, and continuity of long-term management and unmet needs will be assessed from the patient perspective.

研究结论

本研究结果将为临床指南制定提供循证依据,优化医疗资源配置,并为相关政策改革提供支持,从而提高中国肝硬化诊疗服务的质量、公平性和效率。

Conclusion:The findings will provide evidence to inform clinical guidelines, optimize resource allocation, and support policy reforms aimed at improving the quality, equity, and efficiency of cirrhosis care in China.

三 4033

基于电子顺磁共振技术的血清白蛋白结合功能检测方法及其临床应用

Clinical Application of Serum Albumin Binding Function Detection Method Based on Electron Paramagnetic Resonance

作者:Wen Xie¹, Ge Yidi¹

1 Beijing Ditan Hospital

研究背景

白蛋白是反映肝脏合成功能的重要蛋白质。在肝脏疾病进展过程中,白蛋白的结构完整性及其结合功能往往受到损害,而传统的血清总白蛋白浓度检测难以准确反映白蛋白的真实功能状态。

本研究旨在建立并验证一种基于电子顺磁共振(EPR)技术的血清白蛋白结合功能检测方法,并评估其在乙型肝炎相关肝脏疾病不同进展阶段中的应用价值。

Background:MAs an important protein that reflects the synthetic function of the liver, the structural integrity and binding function of albumin are often damaged during the progression of liver disease, and the traditional total albumin concentration detection is difficult to accurately reflect the true functional state of albumin. This research aims to establish and verify a serum albumin binding function detection method based on Electron paramagnetic resonance (EPR) technology, and verify its application in different evolutionary stages of hepatitis B-related liver disease.

研究方法

本研究采用电子顺磁共振(EPR)技术进行检测,以16-氮氧自由基标记硬脂酸(16-DSA)作为自旋探针。按照年龄、性别及基础疾病匹配的原则,共纳入180例研究对象,分为6组,包括慢性乙型肝炎组、乙型肝炎肝硬化组、肝细胞癌组及健康对照组等。研究通过谱图拟合方法分析EPR光谱。

人血白蛋白(HSA)与16-DSA结合后形成的复合物,其实验光谱主要由三种不同成分构成,即强结合成分、弱结合成分和游离成分。其中:强结合成分:代表与白蛋白分子以较高结合强度结合的探针部分。弱结合成分:反映探针与白蛋白之间中等强度的结合状态。游离成分:代表未与白蛋白结合的游离探针分子。在保持探针与白蛋白摩尔比例恒定的条件下,光谱中游离成分所占比例越高,说明白蛋白与外源性分子的综合结合能力越弱,即白蛋白结合功能越差。本研究经北京地坛医院伦理委员会批准。

研究整合患者及医生访谈、病历资料提取和问卷调查等多种数据收集方式。定性访谈主要关注患者诊疗路径、白蛋白使用体验、经济负担及长期疾病管理情况,以分析临床决策过程及其影响因素。定量研究数据则包括肝硬化疾病分期、并发症、医疗服务可及性、经济负担以及白蛋白的使用模式等。

Methods:This study uses EPR technology as the detection method, and uses 16-bit nitrogen oxide free radical labeling stearic acid as a spin probe. Based on the principles of age, gender and underlying disease matching, the study included a total of 180 cases in six groups, including chronic hepatitis B, hepatitis B cirrhosis, hepatocellular carcinoma and healthy control groups.

Analyze the EPR spectrum through the spectrum fitting methods. The experimental spectrum of the complex formed after the combination of HSA and 16-DSA is mainly composed of three different components, namely the strong-binding component, the weak-binding component and the free component. Among them, the strong binding component corresponds to the probe part that binds to the albumin molecule with high intensity; the weak binding component reflects the medium-strength binding state between the probe and the albumin; the free component represents the free probe molecule that is not bound to albumin.

Under the condition that the molar ratio of the probe and albumin remains constant, the higher the proportion of free components in the total spectrum, indicating that the comprehensive binding ability of albumin to foreign molecules is weaker, that is, the binding performance is poor. This research was approved by the Ethics Committee of Ditan Hospital. (AF/SS-21/05.2)

 研究结果

通过对EPR检测条件进行系统优化,本研究建立了一套血清白蛋白结合功能检测方法,具有较高的检测准确性和良好的检测效率。

在此基础上,研究进一步开展了检测和验证。结果显示,随着肝脏疾病严重程度的增加,白蛋白结合功能呈逐渐下降趋势。

Results:Based on the system optimization of EPR detection conditions, this study has established a set of serum albumin binding function detection methods with high accuracy and excellent detection efficiency. On the basis of this study, this study further carried out testing and verification. This study results showed that the albumin binding function gradually decreased with the severity of liver disease.

研究结论

本研究基于电子顺磁共振技术开展血清白蛋白结合功能检测,通过进一步优化检测条件,建立了更加高效的检测流程。

通过在肝脏疾病不同阶段进行验证,研究发现,随着乙型肝炎相关肝脏疾病严重程度的加重,白蛋白结合功能逐渐下降。

Conclusion:Based on EPR technology to detect serum albumin binding function technology, this study further optimizes the detection conditions to establish a more efficient detection process. Through verification in different stages of liver disease, it was found that albumin binding function gradually decreased with the aggravation of the severity of hepatitis B-related liver disease.

四 1667

艾米替诺福韦对合并代谢功能障碍相关脂肪性肝病的慢性乙型肝炎患者肝脏硬度测量值的影响:一项真实世界研究

Impact of Tenofovir Amibufenamide on Liver Stiffness Measurement in Chronic Hepatitis B Patients with Concomitant MASLD: A Real-World Study

作者:Wen Xie¹, Jingjing Wang¹, Wenya Chen¹, Qi Wang¹, Hong Zhao¹, Liugai Liu¹

1 Beijing Ditan Hospital, Capital Medical University

研究背景

艾米替诺福韦(Tenofovir amibufenamide,TMF)是中国自主研发的慢性乙型肝炎(CHB)一线抗病毒药物。

代谢功能障碍相关脂肪性肝病(MASLD)是慢性乙型肝炎患者常见的合并症,可能影响抗病毒治疗后肝脏硬度测量值(LSM)的改善。

然而,目前关于TMF在合并MASLD的慢性乙型肝炎患者中的治疗效果,仍需要更多证据支持。

Background:Tenofovir amibufenamide (TMF) is a Chinese original first-line antiviral agent for the treatment of chronic hepatitis B (CHB). Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity in CHB patients and may influence the improvement of liver stiffness measurement (LSM) following antiviral therapy. However, more evidence is needed regarding the efficacy of TMF in CHB patients with concomitant MASLD.

研究方法

本研究为一项回顾性真实世界研究,共纳入192例接受TMF单药治疗至少48周的慢性乙型肝炎患者,其中74例(38.5%)基线时合并MASLD。

所有患者均在治疗基线及治疗第48周接受瞬时弹性成像检查(FibroScan),记录肝脏硬度测量值(LSM)和受控衰减参数(CAP)。

根据设备操作说明,LSM正常上限设定为7.0 kPa,CAP正常上限设定为238 dB/m。

主要研究终点为LSM较基线下降至少30%的患者比例。研究比较了两组患者LSM下降情况、病毒学抑制情况(HBV DNA<20 IU/mL)、ALT复常情况(≤40 U/L)及血脂谱变化。

Methods:This retrospective real-world study enrolled 192 CHB patients who received TMF monotherapy for at least 48 weeks, including 74 (38.5%) with baseline MASLD. All patients underwent transient elastography (FibroScan) at baseline and week 48 to record LSM and controlled attenuation parameter (CAP).

According to the device operating instructions, the upper limit of normal LSM was 7.0 kPa, and the upper limit of normal CAP was 238 dB/m. The primary endpoint was the proportion of patients with a ≥ 30% decline in LSM from baseline. Changes in LSM decline, virologic suppression (HBV DNA < 20 IU/mL), ALT normalization ( ≤ 40 U/L), and lipid profiles were compared between the two groups.

 研究结果

基线时,两组患者的LSM中位数均处于正常范围,均为6.6 kPa。

治疗48周后,MASLD组LSM较基线下降至少30%的患者比例为18.9%,非MASLD组为26.3%,两组之间差异无统计学意义(P=0.242)。

两组患者的病毒学抑制率分别为77.0%和82.2%(P=0.381),ALT复常率分别为85.5%和87.0%(P=0.772),两项指标在组间均未发现显著差异。

在MASLD组内部分析中,CAP下降至少30 dB/m的患者共28例,占43.8%。与CAP未改善的患者相比,这部分患者LSM下降至少30%的比例更高,分别为28.6%和8.3%,差异具有统计学意义(P=0.047)。

血脂分析显示,MASLD组患者的甘油三酯水平有所下降,由1.38 mmol/L降至1.09 mmol/L,差异具有统计学意义(P=0.031);而总胆固醇、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)水平均保持稳定,差异均无统计学意义(均P>0.05)。

Results:At baseline, median LSM was within the normal range in both groups (6.6 kPa for both). After 48 weeks of treatment, the proportion of patients with a ≥ 30% decline in LSM was 18.9% in the MASLD group and 26.3% in the non-MASLD group, with no statistically significant difference between the two groups (P = 0.242).

Virologic suppression rates (77.0% vs. 82.2%, P = 0.381) and ALT normalization rates (85.5% vs. 87.0%, P = 0.772) were also similar between the two groups.

Within the MASLD group, patients with a ≥ 30 dB/m decline in CAP (n = 28, 43.8%) had a higher proportion of ≥ 30% LSM decline compared to those without CAP improvement (28.6% vs. 8.3%, P = 0.047).

Lipid profile analysis showed a decrease in triglyceride levels in the MASLD group (1.38 vs. 1.09 mmol/L, P = 0.031), while total cholesterol, HDL, and LDL remained stable (all P > 0.05).

研究结论

本研究主要得出三项发现。

第一,对于基线LSM处于正常范围的慢性乙型肝炎患者,合并MASLD并未影响TMF治疗48周后LSM下降、病毒学抑制及ALT复常的效果。

第二,肝脏脂肪变性的改善与更高比例的LSM下降相关,提示代谢控制可能有助于增强抗纤维化治疗效果。

第三,TMF治疗期间患者的血脂谱总体保持稳定,甘油三酯呈下降趋势,未观察到明显的不良代谢影响。

综上,作为中国自主研发的一线抗病毒药物,TMF在合并MASLD的慢性乙型肝炎患者中表现出稳定的抗病毒疗效和良好的代谢安全性。

Conclusion:This study yields three main findings. First, in CHB patients with baseline LSM within the normal range, the presence of MASLD did not affect the efficacy of TMF in achieving LSM decline, virologic suppression, or ALT normalization after 48 weeks of treatment.

Second, improvement in hepatic steatosis was associated with a higher proportion of LSM decline, suggesting that metabolic control may enhance anti-fibrotic efficacy.

Third, lipid profiles remained stable during TMF treatment, with a trend toward decreased triglycerides and no adverse metabolic effects.

In summary, TMF, as a Chinese original first-line antiviral agent, offers both consistent antiviral efficacy and favorable metabolic safety in CHB patients with concomitant MASLD.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言

来源:梅斯医学·临床资讯 · news.medsci.cn